Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18795731 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA | August 2024 | October 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18795683 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA | August 2024 | October 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18795711 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA | August 2024 | October 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18758007 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA | June 2024 | December 2024 | Allow | 6 | 1 | 0 | No | No |
| 18444485 | Compositions comprising pharmaceutically acceptable salts of amylin analogs and uses thereof | February 2024 | April 2025 | Allow | 14 | 2 | 1 | No | No |
| 18443689 | NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENS | February 2024 | May 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18430003 | NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENS | February 2024 | January 2025 | Abandon | 11 | 1 | 0 | No | No |
| 18421405 | LOSARTAN LIQUID FORMULATIONS AND METHODS OF USE | January 2024 | July 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18518100 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA | November 2023 | February 2024 | Allow | 3 | 1 | 0 | No | No |
| 18518110 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA | November 2023 | March 2024 | Allow | 4 | 0 | 0 | Yes | No |
| 18518093 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA | November 2023 | April 2024 | Allow | 4 | 1 | 0 | No | No |
| 18490197 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA | October 2023 | January 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18490188 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA | October 2023 | January 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18470280 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | September 2023 | December 2024 | Allow | 14 | 2 | 1 | No | No |
| 18448312 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA | August 2023 | January 2024 | Allow | 5 | 0 | 0 | Yes | No |
| 18448347 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA | August 2023 | October 2023 | Allow | 2 | 0 | 0 | Yes | No |
| 18448309 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA | August 2023 | October 2023 | Allow | 2 | 0 | 0 | Yes | No |
| 18448333 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREA | August 2023 | September 2023 | Allow | 2 | 0 | 0 | Yes | No |
| 18229728 | ALUMINOSILICATE GLASS WITH PHOSPHORUS AND POTASSIUM | August 2023 | June 2024 | Allow | 11 | 2 | 1 | No | Yes |
| 18361981 | Dendritic Macroporous Hydrogels Prepared By Crystal Templating | July 2023 | March 2024 | Allow | 7 | 1 | 0 | No | No |
| 18216890 | NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENS | June 2023 | February 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18144800 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | May 2023 | February 2025 | Allow | 21 | 1 | 0 | Yes | No |
| 18251929 | COMPOSITION FOR TREATING AND/OR PREVENTING FUNGAL INFECTIONS | May 2023 | December 2023 | Allow | 7 | 1 | 0 | Yes | No |
| 18246151 | COMPOSITIONS COMPRISING REACTION PRODUCTS OF SACCHARIDE POLYMERS AND FATTY ESTERS FORMULATED WITH A NEUTRAL SURFACTANT | March 2023 | December 2023 | Allow | 9 | 1 | 0 | Yes | No |
| 18178789 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHENYL)-3-PHENYLUREA | March 2023 | July 2023 | Allow | 5 | 1 | 0 | Yes | No |
| 18044015 | USE, IN AQUEOUS-ALCOHOLIC COMPOSITIONS, OF A COPOLYMER OBTAINED BY PRECIPITATION POLYMERIZATION | March 2023 | March 2025 | Abandon | 24 | 3 | 0 | Yes | No |
| 18151846 | ONAPRISTONE EXTENDED-RELEASE COMPOSITIONS AND METHODS | January 2023 | November 2023 | Abandon | 10 | 1 | 0 | No | No |
| 18094050 | AMORPHOUS NILOTINIB MICROPARTICLES AND USES THEREOF | January 2023 | March 2024 | Allow | 14 | 3 | 0 | Yes | No |
| 18148766 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHENYL)-3-PHENYLUREA | December 2022 | June 2023 | Allow | 5 | 1 | 0 | No | No |
| 18090582 | AMORPHOUS NILOTINIB MICROPARTICLES AND USES THEREOF | December 2022 | February 2024 | Allow | 13 | 3 | 0 | Yes | No |
| 18089338 | AMORPHOUS NILOTINIB MICROPARTICLES AND USES THEREOF | December 2022 | February 2024 | Allow | 14 | 3 | 0 | Yes | No |
| 18064222 | METHODS OF EFFICIENTLY TREATING VITAMIN C DEFICIENCY-RELATED DISEASES AND OTHER CONDITIONS | December 2022 | May 2024 | Allow | 17 | 3 | 0 | Yes | No |
| 17993422 | NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENS | November 2022 | November 2023 | Allow | 11 | 2 | 0 | Yes | No |
| 18052116 | LOSARTAN LIQUID FORMULATIONS AND METHODS OF USE | November 2022 | December 2023 | Allow | 13 | 2 | 1 | Yes | No |
| 18050951 | METHOD OF MANUFACTURING ANTIFOULING COATING POLYMER USING INITIATED CHEMICAL VAPOR DEPOSITION | October 2022 | May 2025 | Allow | 31 | 2 | 0 | No | No |
| 18047964 | PROCESS FOR MESALAZINE SOLID FORMULATIONS | October 2022 | October 2024 | Allow | 24 | 1 | 0 | Yes | No |
| 18046778 | METHOD OF PREPARING NANOPARTICLES BY HOT-MELT EXTRUSION | October 2022 | December 2024 | Allow | 26 | 2 | 0 | No | No |
| 17965633 | STABILIZING VITAMIN C TOPICAL FORMULATIONS | October 2022 | June 2025 | Allow | 32 | 4 | 1 | Yes | No |
| 17932453 | OPHTHALMIC FORMULATIONS OF METHOTREXATE | September 2022 | March 2024 | Allow | 18 | 2 | 1 | Yes | No |
| 17932426 | OPHTHALMIC FORMULATIONS OF METHOTREXATE | September 2022 | March 2024 | Allow | 18 | 2 | 1 | Yes | No |
| 17900953 | ANTIMICROBIAL GLASS COMPOSITIONS, GLASSES AND POLYMERIC ARTICLES INCORPORATING THE SAME | September 2022 | March 2025 | Abandon | 31 | 1 | 0 | No | No |
| 17816486 | VALPROIC ACID FOR THE TREATMENT OR PREVENTION OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH EXCESS FIBRIN DEPOSITION AND/OR THROMBUS FORMATION | August 2022 | December 2024 | Allow | 29 | 1 | 0 | No | No |
| 17866939 | AMORPHOUS NILOTINIB MICROPARTICLES AND USES THEREOF | July 2022 | February 2024 | Allow | 19 | 4 | 1 | Yes | No |
| 17862421 | METHOD FOR PREPARING PEI-LIPID NANOPARTICLES USED FOR DELIVERING A MRNA VACCINE AND TRANSFECTING STEM CELLS | July 2022 | October 2024 | Allow | 27 | 1 | 0 | No | No |
| 17790808 | SOLUBLE MELATONIN TRIPARTATE ADDUCT FOR THE PREVENTION AND TREATMENT OF RARE AND SEVERE EYE SIGHT-THREATENING CONDITIONS AND NEURO-OPHTHALMIC DISORDERS | July 2022 | March 2023 | Allow | 9 | 1 | 0 | Yes | No |
| 17843769 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | June 2022 | December 2022 | Allow | 6 | 0 | 0 | No | No |
| 17838364 | HAIR CARE COMPOSITIONS COMPRISING HYDROXYLATED TRIGLYCERIDE OLIGOMERS | June 2022 | May 2024 | Allow | 23 | 2 | 0 | Yes | No |
| 17774845 | COMPOSITION WITH SUPERABSORBENT POLYMER | May 2022 | May 2025 | Allow | 36 | 1 | 0 | Yes | No |
| 17735820 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHENYL)-3-PHENYLUREA | May 2022 | December 2022 | Allow | 7 | 1 | 0 | Yes | No |
| 17773995 | PYRIDYLOXYACETIC ACID COMPOUND AND USE OF SAME | May 2022 | May 2025 | Allow | 36 | 1 | 1 | Yes | No |
| 17722688 | ALUMINOSILICATE GLASS WITH PHOSPHORUS AND POTASSIUM | April 2022 | April 2023 | Allow | 12 | 2 | 1 | Yes | Yes |
| 17715355 | PHOTOPROTECTIVE COMPOSITIONS COMPRISING A DIBENZOYLMETHANE DERIVATIVE, A MEROCYANINE COMPOUND AND A COMPOUND CAPABLE OF ACCEPTING THE TRIPLET EXCITED LEVEL ENERGY OF THE DIBENZOYLMETHANE COMPOUND | April 2022 | November 2023 | Abandon | 19 | 1 | 0 | No | No |
| 17692521 | SOFT GELATIN CAPSULES CONTAINING A MIXTURE OF ANALGESICS AND DECONGESTANTS, EXPECTORANTS, ANTITUSSIVES AND/OR ANTIHISTAMINES | March 2022 | May 2023 | Allow | 14 | 0 | 0 | Yes | No |
| 17686373 | SUSPENSION COMPONENT-SPECIFIC TRIAMCINOLONE AND MOXIFLOXACIN COMPOSITIONS AND ASSOCIATED METHODS OF USE | March 2022 | April 2022 | Allow | 1 | 0 | 0 | Yes | No |
| 17686371 | LIMITED PARTICLE SIZE TRIAMCINOLONE AND MOXIFLOXACIN COMPOSITIONS AND ASSOCIATED METHODS OF USE | March 2022 | May 2022 | Allow | 2 | 0 | 0 | Yes | No |
| 17686368 | MOXIFLOXACIN AND TRIAMCINOLONE COMPOSITIONS AND ASSOCIATED METHODS | March 2022 | April 2022 | Allow | 1 | 0 | 0 | Yes | No |
| 17592700 | Choline Esters | February 2022 | March 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17591250 | INDANE DERIVATIVES FOR MALODOR COUNTERACTION | February 2022 | November 2024 | Abandon | 34 | 1 | 1 | No | No |
| 17590213 | Vaginal Hydrogel | February 2022 | August 2023 | Allow | 18 | 1 | 0 | Yes | No |
| 17584997 | ANTI-AGING DRUG COMBINATION AND USE THEREOF | January 2022 | September 2024 | Allow | 32 | 1 | 1 | Yes | No |
| 17628021 | NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENS | January 2022 | February 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17576943 | VETERINARY BROMHEXINE HYDROCHLORIDE SOLUBLE POWDER, PREPARATION METHOD AND USE THEREOF | January 2022 | January 2024 | Abandon | 24 | 2 | 1 | No | No |
| 17547975 | OPHTHALMIC SHIELD AND THERAPEUTIC APPARATUS | December 2021 | June 2025 | Allow | 42 | 2 | 0 | Yes | No |
| 17544630 | Targeting Microbubbles | December 2021 | December 2022 | Allow | 12 | 1 | 0 | Yes | No |
| 17615694 | STABLE MICROBICIDE COMPOSITION | December 2021 | May 2025 | Allow | 42 | 5 | 0 | Yes | Yes |
| 17533461 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | November 2021 | June 2023 | Allow | 19 | 1 | 0 | Yes | No |
| 17455563 | DEFOAMER USEFUL IN A PERACID COMPOSITION WITH ANIONIC SURFACTANTS | November 2021 | June 2025 | Allow | 43 | 4 | 0 | Yes | No |
| 17595192 | ORGANIC ACID SALT OF NICOTINAMIDE RIBOSIDE, COMPOSITION INCLUDING ORGANIC ACID SALT, AND PREPARATION METHODS OF ORGANIC ACID SALT AND COMPOSITION | November 2021 | August 2022 | Allow | 9 | 0 | 0 | Yes | No |
| 17522548 | COMPOUNDS FOR PRENATAL TREATMENT COMPRISIING A NATAL VITAMIN AND ASPIRIN AND METHOD FOR MAKING AND USING THE SAME | November 2021 | November 2023 | Abandon | 25 | 1 | 0 | No | No |
| 17488061 | Methods and Formulations for Preventing Neurological or Psychiatric Disorders | September 2021 | August 2024 | Abandon | 35 | 2 | 0 | No | No |
| 17479886 | GAMMA-HYDROXYBUTYRATE COMPOSITIONS AND THEIR USES FOR THE TREATMENT OF DISORDERS | September 2021 | September 2023 | Abandon | 24 | 3 | 1 | Yes | No |
| 17477361 | LOW-BURST POLYMERS AND METHODS TO PRODUCE POLYMER | September 2021 | March 2023 | Allow | 18 | 1 | 0 | No | No |
| 17474656 | Onychomycosis Treatment Compositions and Methods | September 2021 | May 2022 | Allow | 8 | 1 | 1 | Yes | No |
| 17470891 | Taxane Analogs for the Treatment of Brain Cancer | September 2021 | June 2023 | Allow | 21 | 1 | 0 | No | No |
| 17467752 | CHITOOLIGOSACCHARIDES AND METHODS FOR USE IN ENHANCING PLANT GROWTH | September 2021 | September 2024 | Allow | 36 | 3 | 0 | Yes | No |
| 17466189 | METHODS AND COMPOSITIONS FOR ANTIMICROBIAL TREATMENT | September 2021 | December 2023 | Allow | 28 | 3 | 0 | Yes | No |
| 17458533 | PREDNISOLONE AND MOXIFLOXACIN COMPOSITIONS AND METHODS | August 2021 | February 2024 | Allow | 30 | 6 | 1 | Yes | No |
| 17458523 | TRIAMCINOLONE AND MOXIFLOXACIN COMPOSITIONS | August 2021 | December 2021 | Allow | 3 | 0 | 0 | Yes | No |
| 17393196 | FORMULATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITORS | August 2021 | March 2025 | Abandon | 43 | 2 | 1 | No | No |
| 17364199 | Long acting drug delivery device and its use in contraception | June 2021 | March 2025 | Allow | 44 | 3 | 1 | Yes | No |
| 17361471 | PHARMACEUTICAL FORMULATION CONTAINING COMBINATION OF M3 ANTAGONIST-BETA-2 AGONIST AND INHALED CORTICOSTEROIDS | June 2021 | September 2022 | Abandon | 14 | 2 | 0 | No | No |
| 17360852 | NITRIC OXIDE RELEASING PHARMACEUTICAL COMPOSITIONS | June 2021 | June 2024 | Abandon | 36 | 2 | 1 | No | No |
| 17350110 | Use of short chain fatty acids for the treatment and prevention of diseases and disorders | June 2021 | April 2023 | Allow | 22 | 1 | 0 | Yes | No |
| 17337095 | USE OF CYSTEAMINE AND DERIVATIVES THEREOF TO SUPPRESS TUMOR METASTASES | June 2021 | August 2023 | Allow | 26 | 1 | 0 | No | No |
| 17336412 | PREVENTION OF THE WRINKLING AND EXPRESSION OF HUMAN SKIN | June 2021 | January 2025 | Abandon | 43 | 3 | 0 | No | No |
| 17335496 | D2O STABILIZED PHARMACEUTICAL FORMULATIONS | June 2021 | May 2024 | Allow | 35 | 2 | 1 | No | No |
| 17335490 | D2O STABILIZED PHARMACEUTICAL FORMULATIONS | June 2021 | July 2024 | Allow | 37 | 4 | 0 | Yes | No |
| 17327203 | ESLICARBAZEPINE SUSPENSION | May 2021 | March 2022 | Allow | 10 | 1 | 1 | Yes | No |
| 17321905 | ANTIMICROBIAL GLASS COMPOSITIONS, GLASSES AND POLYMERIC ARTICLES INCORPORATING THE SAME | May 2021 | June 2022 | Allow | 13 | 0 | 0 | Yes | No |
| 17322316 | COMPOSITIONS AND METHODS OF TREATING COGNITIVE IMPAIRMENT | May 2021 | November 2021 | Allow | 6 | 1 | 0 | Yes | No |
| 17316020 | ANTIMICROBIAL GLASS COMPOSITIONS, GLASSES AND POLYMERIC ARTICLES INCORPORATING THE SAME | May 2021 | June 2022 | Allow | 14 | 0 | 0 | Yes | No |
| 17313296 | METHODS OF MODULATING IMMUNE ACTIVITY | May 2021 | March 2022 | Allow | 10 | 2 | 1 | Yes | No |
| 17307275 | METHODS AND COMPOSITIONS FOR TREATING MEIBOMIAN GLAND DYSFUNCTION | May 2021 | November 2022 | Allow | 18 | 3 | 0 | Yes | No |
| 17238869 | AMORPHOUS NILOTINIB MICROPARTICLES AND USES THEREOF | April 2021 | March 2022 | Allow | 11 | 2 | 1 | Yes | No |
| 17231653 | Dendritic Macroporous Hydrogels Prepared By Crystal Templating | April 2021 | July 2023 | Allow | 27 | 2 | 0 | Yes | No |
| 17217760 | CETIRIZINE OPHTHALMIC COMPOSITIONS | March 2021 | December 2022 | Abandon | 20 | 4 | 0 | Yes | No |
| 17206226 | SOLID PHARMACEUTICAL TABLET | March 2021 | March 2023 | Allow | 24 | 1 | 0 | Yes | No |
| 17202238 | MIDODRINE HYDROCHLORIDE ORAL SOLUTION AND USES THEREOF | March 2021 | March 2024 | Abandon | 36 | 1 | 1 | No | No |
| 17192709 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | March 2021 | September 2021 | Allow | 7 | 1 | 1 | Yes | No |
| 17188492 | METHODS FOR CANCER THERAPY | March 2021 | November 2021 | Allow | 9 | 0 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ALLEY, GENEVIEVE S.
With a 10.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 32.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner ALLEY, GENEVIEVE S works in Art Unit 1617 and has examined 746 patent applications in our dataset. With an allowance rate of 60.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 31 months.
Examiner ALLEY, GENEVIEVE S's allowance rate of 60.6% places them in the 14% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by ALLEY, GENEVIEVE S receive 2.23 office actions before reaching final disposition. This places the examiner in the 76% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by ALLEY, GENEVIEVE S is 31 months. This places the examiner in the 34% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +53.1% benefit to allowance rate for applications examined by ALLEY, GENEVIEVE S. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 23.1% of applications are subsequently allowed. This success rate is in the 22% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 30.5% of cases where such amendments are filed. This entry rate is in the 36% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 62.5% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 49% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 65.5% of appeals filed. This is in the 41% percentile among all examiners. Of these withdrawals, 55.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 51.6% are granted (fully or in part). This grant rate is in the 64% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.1% of allowed cases (in the 47% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.4% of allowed cases (in the 48% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.